fosinopril / Generic mfg. - LARVOL DELTA

Synergistic in-vitro activity of Fosinopril alone and in combination with imidocarb dipropionate against Babesia bovis. (PubMed, Front Vet Sci) - "Overall, these proof-of-concept in-vitro findings suggest that Fosinopril has potential as a repurposed therapeutic agent for the treatment of B. bovis-infection in cattle. Low-dose Fosinopril-ID combinations may provide a dose-sparing direction for future pharmacological studies."

Journal • Preclinical • Infectious Disease

Target-dose vs below-target-dose lisinopril and fosinopril in HFrEF with advanced CKD. (PubMed, Eur J Heart Fail) - No abstract available

Journal • Cardiovascular

Digital pharmacoepidemiology of angiotensin-converting enzyme inhibitors in Russia. (PubMed, Front Pharmacol) - "Search queries were analyzed for six major ACE inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril, fosinopril), as well as for their brand names (21 drugs in total). The identified digital patterns may indirectly reflect medication-related information needs and potential gaps in the population's health literacy. The infodemiological approach represents a promising tool for monitoring patients' information needs and optimizing clinical communication and preventive programs."

Journal • Cardiovascular • Hypertension

Paeoniflorin attenuates cardiac remodeling by targeting AKT1 and suppressing the AKT/NF-κB inflammatory axis. (PubMed, Mol Biol Rep) - "Pae alleviates HF by targeting the AKT1/NF-κB signaling axis to mitigate pathological remodeling and inflammation, presenting a safe and promising therapeutic candidate for heart failure management."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • IL1B • IL6 • TNFA

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Recruiting | Sponsor: Policlinico San Donato S.p.A. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Adverse event of ACE inhibitors: A descriptive analysis of FAERS data. (PubMed, J Public Health Res) - "This retrospective pharmacovigilance study analyzed FAERS reports submitted from January 1, 1979, through March 31, 2025, for nine ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, and trandolapril) identified as primary suspect drugs. Adults and elderly patients carry the highest burden of ADEs, though pediatric cases remain clinically relevant for specific agents. These findings support tailored monitoring and risk mitigation strategies in clinical practice."

Adverse events • Journal • Acute Kidney Injury • Cardiovascular • Cough • Hypertension • Hypotension • Nephrology • Pediatrics • Renal Disease • Respiratory Diseases

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD) (clinicaltrials.gov) - P4 | N=64 | Active, not recruiting | Sponsor: Baylor Research Institute

New P4 trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Pediatric oral antihypertensive agents: analysis of prescription patterns and patient characteristics in a real-world study. (PubMed, Front Pediatr) - "Among over-12-year-olds, DUI 1.1 for hydrochlorothiazide, amlodipine, ramipril and fosinopril. Pediatric oral hypertension dosing remains inconsistent in clinical practice. These findings support sex-specific management and guideline updates to improve blood pressure control in high-risk adolescents."

Journal • Real-world evidence • Cardiovascular • Hypertension • Pediatrics

Protective effect of Renshen-Danshen on myocardial ischemia-reperfusion injury in rats based on SIRT3/PGC-1α/VDAC1 signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi) - "A rat MIRI model was established and randomly divided into control, model, fosinopril, and low-, medium-, and high-dose RSDS groups...Western blot and RT-qPCR analyses demonstrated that RSDS improved mitochondrial function, inhibited oxidative stress, and protected myocardial cells by regulating the SIRT3/PGC-1α/VDAC1 signaling pathway. In conclusion, RSDS significantly ameliorates cardiac dysfunction induced by MIRI through regulation of the SIRT3/PGC-1α/VDAC1 signaling pathway, reducing myocardial apoptosis, fibrosis, and inflammation."

Journal • Preclinical • Cardiovascular • Fibrosis • Immunology • Myocardial Ischemia • Oncology • Reperfusion Injury • CRP • IL6 • SIRT3 • TNFA • VDAC1

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann

New P4 trial • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann | Unknown status ➔ Recruiting | Trial completion date: Feb 2021 ➔ Dec 2026 | Trial primary completion date: Feb 2019 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Paeoniflorin mitigates myocardial hypertrophy by regulating mitophagy and ferroptosis mediated by mitochondria-associated AMPK-Parkin-ACSL4 pathway. (PubMed, Free Radic Biol Med) - "PF attenuates ISO-induced cardiac hypertrophy by stimulating AMPK-dependent mitophagy and suppressing ferroptosis through the Parkin/ACSL4 pathway. These findings elucidate the molecular basis of PF's cardioprotective function and support its prospective application in addressing abnormal heart remodeling."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Metabolic Disorders • ACSL4

Impact of antihypertensive treatment on cardiovascular event reduction in patients with asymptomatic carotid artery stenosis: a systematic review and meta-analysis. (PubMed, Pan Afr Med J) - "The results reported that enalapril and fosinopril demonstrated dual benefits in blood pressure (BP) reduction and vascular remodeling, though meta-analysis showed statistically insignificant improvements in regional cerebral blood flow (CI: -0.84, 6.08, P = 0.14, I2= 94%). Similarly, isradipine, lacidipine, and amlodipine improved carotid hemodynamics and cerebral perfusion, with meta-analysis favoring calcium channel blocker intervention for blood pressure management (CI: -3.25 to 7.64, P = 0.43)...Moreover, beta-blockers showed specific benefits, with metoprolol improving plaque echogenicity (57.3 ± 16.8 vs. 51.8 ± 20.0, p = 0.006) and reducing cardiovascular events (17% vs. 37% placebo, p = 0.011), while labetalol effectively managed post-endarterectomy hypertension. In conclusion, antihypertensive treatments showed varying effectiveness in cardiovascular event reduction and improvements in vessel measures."

Clinical • Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Hypertension

Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC. (PubMed, Cell Death Discov) - "This study provides the first evidence that fosinopril inhibits NSCLC via GSDME-dependent pyroptosis, triggered by ROS-induced mitochondrial dysfunction and caspase activation. Further investigation into the detailed mechanisms of fosinopril's anti-NSCLC activity is warranted."

Journal • Cardiovascular • Hepatocellular Cancer • Hypertension • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CASP3 • CASP9 • GSDME

Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews. (PubMed, J Clin Med) - "Significant safety signals were detected for amlodipine alone and in combination with aliskiren, specific ACE inhibitors (quinapril, benazepril, trandolapril, fosinopril, perindopril), and certain ARBs (candesartan, losartan). While these results should not discourage appropriate clinical use, they emphasize the importance of monitoring for angioedema, particularly during therapy initiation. The findings from this study need to be validated in prospective studies for further elucidation of the underlying mechanisms."

Adverse events • Journal • Cardiovascular • Hypertension

Effect of intestinal microbiota on adaptation to overcrowding stress in grouper (Epinephelus fuscoguttatus♀×E. lanceolatus♂). (PubMed, Fish Shellfish Immunol) - "The selected four associated metabolites (including creatine, fosinopril, 4-aminobutyric acid, and guanidinopropanoic acid) were validated to significantly reduce the expression of cellular inflammatory factors using the self-established grouper head kidney (HK) cell line. In conclusion, density pressure in the early culture period could affect the stability of the intestinal microbial environment of grouper. As aquaculture time increases, the intestinal microbial community of grouper drives the body's anti-inflammatory response and enhanced its adaptation to density pressure by regulating own structure and secretion of metabolites."

Journal • Inflammation • Inflammatory Bowel Disease • CXCL8 • IL1B • IL6 • TNFA

Fosinopril inhibits Ang II-induced VSMC proliferation, phenotype transformation, migration, and oxidative stress through the TGF-β1/Smad signaling pathway. (PubMed, Open Life Sci) - "Finally, FOS mitigates Ang II-induced VSMC proliferation, phenotypic transformation, migration, and oxidative stress by inhibiting the TGF-β1/Smad signaling pathway. In conclusion, these results suggest that FOS could be effective in managing vascular diseases, including hypertension."

Journal • Cardiovascular • Hypertension • MMP2 • MMP9 • NOX4 • SMAD2 • TGFB1

Effect of calf separation on gut microbiome and fecal metabolome of mother in the captive Yangtze finless porpoise (Neophocaena asiaeorientalis asiaeorientalis). (PubMed, Int Microbiol) - "The fecal metabolome underwent significant changes during social separation, with stress-associated metabolites like kainic acid, phenethylamine glucuronide, and paxilline upregulated in the MC group and host health-associated metabolites like butyric acid, 6-hydroxyhexanoic acid, and fosinopril downregulated in the MS group...The study enhances our comprehension of the detrimental effects of social separation, which result in disruptions in the gut microbiome and fecal metabolome. The study is aimed at introducing a new method for assessing the health and welfare of endangered mammals in captivity."

Journal

Clinical Significance and Patterns of Potential Drug-Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors. (PubMed, J Clin Med) - "The rates of serious and monitor-closely pDDIs due to 'aspirin + captopril' combinations were significantly higher in P-List than in T-List (p-value < 0.05). Obtained data may suggest better patient adherence to 'aspirin + enalapril' and 'aspirin + lisinopril' combinations, which are potentially superior to the combinations of aspirin with fosinopril, perindopril, and ramipril. An abundance of high-order pDDIs in real-world clinical practice warrants the development of a decision support system aimed at reducing pharmacotherapy-associated risks while integrating patient pharmacokinetic, pharmacodynamic, and pharmacogenetic information."

Journal • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

Modified Fangji Huangqi Decoction alleviates renal interstitial fibrosis by inhibiting TGF-β1/Smad/Snail signaling pathway during epithelial-mesenchymal transition (PubMed, Zhongguo Zhong Yao Za Zhi) - "5-fold and 2-fold concentrations of modified Fangji Huangqi Decoction and fosinopril sodium(positive control) for 7 days...After sh RNA silencing of the Snail gene, the protein and m RNA levels of E-cadherin, α-SMA, and vimentin showed no significant differences before and after treatment with the serum containing the decoction. The results suggest that modified Fangji Huangqi Decoction may alleviate renal interstitial fibrosis by inhibiting the TGF-β1/Smad/Snail signaling pathway and regulating the EMT process."

Journal • Fibrosis • Immunology • CDH1 • TGFB1 • VIM

Drugs for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Cardiovascular • Hypertension

Babesia BdFE1 Esterase is Required for the Anti-parasitic Activity of the ACE Inhibitor Fosinopril. (PubMed, J Biol Chem) - "Parasites carrying the L238H mutation in the active site of BdFE1 failed to convert the prodrug to its active moiety and became resistant to the drug. Our data set the stage for the development of this class of drugs for therapy of vector-borne parasitic diseases."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study. (PubMed, Front Pediatr) - "Fosinopril may be particularly effective in reducing BP in hypertensive patients of females, central obesity, IR, and hypo-HDL-cholesterolemia. These findings indicate that optimizing antihypertensive medication selection based on the individualized characteristics of children with hypertension may improve the efficacy of antihypertensive treatment."

Journal • Observational data • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertension • Hypertriglyceridemia • Obesity • Pediatrics

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2. (PubMed, Front Chem) - "We screened ACE inhibitors and previously identified SARS-CoV-2 inhibitors for binding to the RBD-hACE2 interface, and then conducted 500 ns of unrestrained molecular dynamics (MD) simulations of fosinopril, fosinoprilat, lisinopril, emodin, diquafosol, and physcion bound to the interface to assess the binding characteristics of these ligands. However, when lisinopril is bound, it stabilizes the trimeric complex and, therefore, is not an ideal potential drug candidate. Overall, these results reveal important atomistic interactions critical to the binding of the RBD to hACE2 and highlight the significance of including all protein partners in the evaluation of a potential drug candidate."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases